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Postoperative extended-volume 
external-beam radiation therapy 
in high-risk esophageal cancer 
patients: a prospective experience
Results
The study accrued 10 men and 5 women of median 
age 64 years (range: 48–80 years) and TNM stages 
T3N0 (n = 1), T2N1 (n = 2), T3N1 (n = 11), and T4N1 
(n = 1). Histopathology included 5 adenocarcinomas 
and 10 squamous-cell carcinomas. Resection margins 
were clear in 10 patients. The median follow-up time 
was 19 months (range: 3.5–53.4 months). Before 
radiation therapy commenced, delay in chemother-
apy occurred in 20% of patients, and dose reduction 
was required in 13.3%. During the concurrent chemo-
radiation therapy phase, 20% of the patients experi-
enced chemotherapy delay, and 6.6% experienced 
dose reduction. No patient experienced treatment-
related acute and chronic esophagitis above grade 2. 
Disease recurred in 40% of the patients (6/15), and 
median time to relapse was 24 months. No tumour 
recurred at the anastomotic site. The median d f s  was 
23 months, and the median o s  was 21 months.
Conclusions
Extended-volume external-beam r t  encompassing 
the tumour bed and the anastomotic site is feasible 
and safe for high-risk T3–4, N0–1 esophageal cancer 
patients after esophagectomy.
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irradiation
1.  INTRODUCTION
Surgery has traditionally been considered the stan-
dard therapy for localized esophageal cancer 1. Post-
operative radiation therapy (r t) 2,3 and postoperative 
ABSTRACT
Background and Purpose
Extended-volume external-beam radiation therapy 
(r t) following esophagectomy is controversial. The 
present prospective study evaluates the feasibility of 
extended-volume r t  treatment in high-risk esophagec-
tomy patients with a cervical anastomosis receiving 
postoperative combined chemoradiation therapy.
Patients and Methods
From 2001 to 2006, 15 patients with resected esoph-
ageal cancer were prospectively accrued to this pilot 
study to evaluate the adverse effects of extended-
volume r t. Postoperative management was carried 
out at London Regional Cancer Program. Eligibil-
ity criteria were pathology-proven esophageal ma-
lignancy (T3–4, N0–1), disease amenable to surgical 
resection, and esophagectomy with or without resec-
tion margin involvement. Patients with distant me-
tastases (M1) and patients treated with previous r t  
were excluded. All 15 study patients received 
4 cycles of 5-fluorouracil–based chemotherapy. 
External-beam r t  was conducted using conformal 
computed tomography planning, with multi-field 
arrangement tailored to the pathology findings, with 
coverage of a clinical target volume encompassing 
the primary tumour bed and the anastomotic site in 
the neck. The radiation therapy dose was 50.40 Gy 
at 1.8 Gy per fraction. The r t  was delivered concur-
rently with the third cycle of chemotherapy. The 
study outcomes—disease-free survival (d f s) and 
overall survival (o s)—were calculated by the Ka-
plan–Meier method. Treatment-related toxicities 
were assessed using the U.S. National Cancer Insti-
tute’s Common Toxicity Criteria.
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fi g u r e  1   Sample computed tomography simulated radiotherapy 
(r t) portal for extended-volume r t with coverage of anastomotic site 
for esophageal cancer after surgery. m l C  = multileaf collimator; 
C t V   = clinical target volume; r = right; l = left.
chemoradiation 4–6 have been used for esophageal 
cancer patients deemed to be at high risk for recurrence 
after esophagectomy. As compared with surgery alone, 
postoperative chemotherapy and r t  7,8 have been re-
ported to be beneficial with regard to survival.
Optimal r t  target-volume definition in esopha-
geal cancer patients receiving primary chemoradia-
tion is controversial 9, partly because of the significant 
changes in patient anatomy and function, and partly 
because of the limited information available to 
evaluate the benefit on anastomotic site coverage in 
the postsurgical r t  target volume. The literature 
contains limited retrospective or prospective infor-
mation regarding the necessity for irradiation of the 
anastomosis and regarding the safety of the rela-
tively large treatment volume when combined with 
chemotherapy postoperatively. We previously re-
ported a retrospective analysis of extended-volume 
external-beam r t  with a clinical target volume (c t v) 
covering the anastomotic site in post-esophagecto-
my high-risk patients 10. The present study was our 
local prospective pilot trial assessing the feasibility 
of incorporating the extended-volume regimen into 
r t  planning for a postsurgical adjuvant trial in 
esophageal cancer.
2.  PATIENTS AND METHODS
From 2001 to 2006, we prospectively accrued 15 
patients with resected esophageal cancer to this 
pilot study at the London Regional Cancer Program 
to evaluate the adverse effects of postoperative ex-
tended-volume r t  delivered with concurrent chemo-
therapy and of the complications of extended-volume 
r t  concurrent with chemotherapy. Eligibility criteria 
were pathology-proven esophageal malignancy; 
2002 American Joint Committee on Cancer 11 stage 
T3–4, N0–1 disease; and esophagectomy with or 
without resection margin involvement. Patients with 
distant metastasis (M1), those who had received 
previous r t, or those who declined to sign a consent 
form were excluded.
Adjuvant therapy consisted of chemotherapy 
followed by concurrent chemoradiation 4 weeks post 
surgery or as soon as the patient recovered from the 
surgical procedure. Chemotherapy consisted of 
4 cycles of epirubicin 50 mg/m2 day 1, 5-fluorouracil 
200 mg/m2 continuous infusion for 21 days, and 
cisplatin 60 mg/m2 day 1, repeated every 21 days, 
with epirubicin omitted during the concurrent phase 
with r t.
Delivery of the external-beam r t  used conformal 
computed tomography (c t) planning, with a multi-
field arrangement tailored to the pathology findings 
and a c t v encompassing the primary tumour bed and 
the anastomotic site in the neck. The initial r t  target 
volume was defined with margins of 5 cm above and 
below the presurgical gross tumour volume, and a 
2-cm margin to cover the mediastinal lymph nodes 
medially and laterally, with the superior margin 
extended at least 2 cm above the anastomotic site 10 
(Figure 1). The boost fields had minimum 2-cm 
margins around the presurgical target volume. The 
total r t  dose was 50.4 Gy, with 1.8 Gy per fraction 
(initially 30.6 Gy in 17 fractions, followed by 19.8 Gy 
in 11 fractions), delivered concurrently with the third 
cycle of chemotherapy.
Follow-up evaluations of the patients were per-
formed every 3 months during years 1–2, every 
4 months during years 3–4, every 6 months during 
year 5, and annually thereafter. Follow-up investigations 
included screening blood cell count and chemistries, 
chest radiography, and c t of chest and abdomen. At 
the time of relapse, investigations were carried out 
as clinically indicated and included endoscopy; 
barium-swallow esophagram; brain, chest, and ab-
dominal c t; and bone scan.
Local relapse was defined as tumour recurrence 
at or immediately adjacent to the anastomotic site. 
Regional relapse was defined as recurrence at the 
mediastinum or peri-esophageal region (or both), 
excluding local relapse. Distant relapse was tumour 
recurrence at distant site—for example, brain, liver, 
or lung.
Treatment–related toxicities were assessed using 
the U.S. National Cancer Institute (n c i) Common Tox-
icity Criteria. Acute (90 or fewer days from r t  start) YU et al.
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side effects of radiation therapy were documented us-
ing the revised n c i  Common Toxicity Criteria 12.
Grade 2 esophagitis related to r t  was described 
as dysphagia, requiring predominantly pureed, soft, 
or liquid diet for acute effect; inability to take solid 
food normally; swallowing semisolid food; and need 
for dilation for late effect. Late r t  toxicity is defined 
as an adverse event occurring more than 90 days from 
r t  start, according to the Late Radiation Morbidity 
Scoring Scheme from the Radiation Therapy Oncol-
ogy Group (r t o g ) and the European Organization for 
Research and Treatment of Cancer, and the n c i  1999 
Common Toxicity Criteria. Late gastrointestinal r t  
morbidity (r t o g  grading system)—grade 2 toxicity 
described as moderate diarrhea and colic with bowel 
movement more than 5 times daily, or intermittent 
bleeding—was also analyzed.
For the purpose of the study, the marker for any 
toxicity-related treatment break was measured by 
the length (in days) of the interruption in the che-
motherapy or r t  schedule arising during the concur-
rent  phase  of  chemoradiation  treatment. 
Hematologic criteria for interruptions during con-
current chemotherapy r t  included absolute neutro-
phil count below 1000/mm3; neutropenic fever or 
sepsis; thrombocytes below 80,000/mm3. Locore-
gional symptomatology for treatment interruption 
included severe esophagitis (that is, severe 
odynophagia or dysphagia, intolerable pain), im-
paired nutrition with nausea and vomiting; and de-
hydration requiring hospitalization 10.
Overall survival (o s ) was defined as the interval 
between the date of pathology diagnosis and death or 
last follow-up, with any death being defined as an 
event. Disease-free survival (d f s ) was defined as the 
interval between the date of pathology diagnosis and 
the date of first recurrence or last follow-up, with 
recurrence treated as an event. Survival estimates 
were obtained using the Kaplan–Meier method 13.
3.  RESULTS
Table i summarizes the characteristics of the study 
cohort. The 15 subjects (10 men, 5 women) had a 
median age of 64 years (range: 48–80 years). The 
TNM stages in the group were T3N0 (n = 1), T2N1 
(n = 2), T3N1 (n = 11), and T4N1 (n = 1). Histopathol-
ogy included 5 adenocarcinomas and 10 squamous-
cell carcinomas. Surgery was either transhiatal 
(87%) or transthoracic (13%), with clear resection 
margins in 10 patients and a close or positive radial 
resection margin in 5 (Table i). The median follow-
up was 19 months (range: 3.5–53.4 months).
Table ii summarizes the treatment characteristics 
in the patient cohort. Before the start of r t , delay in 
chemotherapy and chemotherapy dose reduction oc-
curred in 20% and 13.3% of the patients respectively. 
During concurrent chemoradiation, these proportions 
were 20% and 6.6%.
These reasons were cited for chemotherapy delay:
Cycle 1: physician and patient choice • 
Cycle 2: febrile neutropenia, diarrhea • 
Cycle 3 (with  •  r t ): neutropenia
Cycle 4 (with  •  r t ): neutropenia and patient choice
These reasons were cited for chemotherapy dose 
reduction:
Cycle 1: no dose reductions • 
Cycle 2: febrile neutropenia, diarrhea, and physi- • 
cian choice
Cycle 3 (with  •  r t ): febrile neutropenia, mucositis, 
hand–foot syndrome
Cycle 4 (with  •  r t ): patient choice
No r t  delays or r t  dose reductions occurred in 
this patient cohort.
During the concurrent chemoradiation treatment 
period, 1 patient experienced grade 1 esophagitis, and 
1 patient, grade 2 nausea and vomiting. The constitu-
tional symptoms observed were moderate taste al-
teration in 2 patients and poor appetite in 3 patients.
During the follow-up period 90 or fewer days 
from r t  start, 2 patients had grade 1 cough, 1 patient 
had grade 1 nausea and vomiting, 1 patient had 
grade 1 esophagitis, 1 patient had grade 2 nausea and 
vomiting, and 1 patient had grade 2 diarrhea and 
abdominal cramps. The constitutional symptoms 
observed were mild-to-moderate taste alteration in 2 
patients and mild poor appetite and low energy level 
in 3 patients.
During the follow-up period more than 90 days 
from r t  start, 2 patients had grade 1 shortness of 
breath; 1 patient had grade 2 pneumonitis; 2 patients 
t a b l e  i  Patient demographics
Age (years)
Median 64
Range 48–80
Sex
Male 10
Female 5
Stage
T3N0 1
T2N1 2
T3N1 11
T4N1 1
Tumour pathology
Squamous-cell 10
Adenocarcinoma 5
Margin status
Clear 10
Close/positive 5POSTOPERATIVE XRT IN HIGH-RISK ESOPHAGEAL CANCER
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had grade 2 dysphagia, difficulty with solid food 
requiring esophagoscopy and dilatation for anasto-
motic strictures; and 2 patients had grade 1 nausea 
and vomiting. The constitutional symptoms observed 
were grade 1 fatigue (increase in fatigue over baseline, 
but not altering normal activities) in 2 patients, mod-
erate taste alteration in 1 patient, and mild poor ap-
petite in 1 patient (Table iii).
No treatment-related esophagitis or pneumonitis 
of greater than grade 2 was observed during treatment 
and in the follow-up assessments. No chemoradiation 
treatment–related mortality occurred in the study 
cohort: specifically, no anastomotic leaks or wound 
breakdown occurred.
Disease recurrence was observed in 40% (6/15) 
of the patients, with median time to relapse being 24 
months (Figure 2). No tumour recurrence at the anas-
tomotic site was observed. Relapses were exclu-
sively distant metastases, with lung and liver as the 
most common sites (Table iv). The median, 1-year, 
and 2-year d f s  and o s  rates were 23 months, 80%, 
and 44% and 21 months, 65%, and 38% respectively.
4.  DISCUSSION
The results of this pilot study are consistent with a 
previous retrospective analysis from our institution 
reporting complications of extended-volume r t  10. The 
current prospective trial confirmed the absence of 
grades 3 and 4 adverse effects with the use of ex-
tended volume r t  concurrent with chemotherapy. Qiao 
and co-workers 14 reviewed 102 cases of squamous 
cell carcinoma of the esophagus receiving postopera-
tive r t  of 50 Gy, in which 43 patients treated with 
extended r t  fields covering supraclavicular nodes, 
anastomotic sites, and loco–tumour bed were com-
pared with 59 patients receiving r t  to the loco–tumour 
bed only. Although o s  differences between the two 
groups were nonsignificant, treatment side effects and 
complications were also nonsignificantly different 
(18.6% vs. 11.9%, p = 0.343), including no difference 
in the degree of severity of nausea and anorexia be-
tween the two groups. No anastomotic leakage, fistu-
lae, or local disease recurrence were observed during 
follow-up.
Benign anastomotic stricture can occur as early 
as 27 days and up to 11 months (median: 2–3 months) 
post transhiatal esophagectomy in esophageal cancer. 
Depending on the surgical technique, the anasto-
motic stricture rate from some surgical series can be 
as high as 42% 15–17. Singh and co-workers 17 reported 
that patients who underwent total mechanical anas-
tomosis experienced anastomotic stricture requiring 
dilation at a rate of 18%. Our current prospective 
t a b l e  ii  Chemotherapy delay and dose reduction (d r ) in the study 
patients
Patient Chemotherapy cycle
id 1 2 3+r t 4+r t
Delay d r Delay d r Delay d r Delay d r
1 – – – – – – – –
2 – – – – + – + +
3 – – – – – – – –
4 – – – – + – + –
5 – – – – – + – –
6 + – – + – – – –
7 – – + – – + – –
8 – – – – – – – –
9 – – + + – – + –
10 – – + – + – – –
11 – – – – – + – –
12 – – – – – – – –
13 – – – – – – – –
14 – – – – – – – –
15 – – – – – – – –
Overall (%) 6.6 0 20 13.3 20 20 20 6.6
id = identification number; r t  = radiotherapy.
t a b l e  iii  Side effects and complications in the study patients
Adverse Days from radiotherapy start
events ≤90 >90
Event gradea Event gradeb
1 2 3 4 1 2 3 4
Lungc [n (%)] 2 (13) 0 0 0 2 (13) 1 (7) 0 0
Small/large boweld [n (%)] 1 (7) 2 (13) 0 0 2 (13) 0 0 0
Esophaguse [n (%)] 1 (7) 0 0 0 0 2 (13) 0 0
Constitutional symptomsf [n (%)] 3 (20) 2 (13) 0 0 3 (20) 1 (7) 0 0
a  According to the U.S. National Cancer Institute Common Toxicity Criteria.
b    According to Radiation Therapy Oncology Group/European Organization for the Research and Treatment of Cancer late radiation mor-
bidity scoring.
c  Pneumonitis, cough.
d  Nausea, diarrhea.
e  Esophagitis, dysphagia.
f  Taste alteration, poor appetite, fatigue.YU et al.
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study found a rate of 13% (2 patients) of anasto-
motic stricture post esophagectomy while receiving 
adjuvant chemoradiation.
Although the median follow-up in our patient 
cohort is 19 months at the time of writing, any ad-
ditional adverse effects from the development of 
anastomotic stricture while receiving adjuvant 
chemoradiation have yet to occur. Distinct from the 
finding in our previous retrospective study of 15% 
locoregional relapse with a median follow-up of 30 
months after extended-volume r t, the current pilot 
study, with a shorter median follow-up (19 months), 
has yet to identify any locoregional recurrence. In 
the current study, the recurrences (40%) were all in 
distant sites, with liver and lung being the most com-
mon sites. That result is consistent with our previous 
report that 85% of relapses in patients treated with 
extended-volume r t  are distant failures.
Although some surgical series have reported that 
anastomotic recurrence rates are as low as under 
5% 18,19, autopsy studies of patients with advanced 
tumours have reported tumour at the anastomosis in 
almost 30% of cases 20. Consistent with those studies, 
our previous series reported a 29% anastomotic re-
currence rate for high-risk patients in whom the r t  
volume did not include the anastomotic site.
Xiao et al. 21 reported a series of 549 cases of 
squamous cell carcinoma of the esophagus. Postopera-
tive r t  with 50–60 Gy significantly reduced the inci-
dence of intrathoracic recurrence in high-risk patients 
with positive nodes and also in patients with negative 
nodes. Our current data are consistent with our previous 
series and similar to data reported by Xiao et al. 21, find-
ing that high-risk patients treated with r t  encompassing 
the anastomosis have not experienced anastomotic site 
recurrence and that postoperative r t  reduces the risk of 
intrathoracic recurrence.
The optimal dose for postoperative r t  in esoph-
ageal cancer is also controversial. Much of the infor-
mation on r t  dose has been derived from reports of 
preoperative management, with a prescribed r t  dose 
of 30 Gy to the regional nodes and a boost of 20 Gy 
to the primary tumour, delivered with chemotherapy. 
This regimen is superior to 64 Gy of r t  alone without 
chemotherapy 22. Regimens using a higher r t  dose 
level of 64.8 Gy have been reported not to be supe-
rior to 50.4 Gy concurrently with chemotherapy 23. 
In a single-institution study, Yu et al. 10 reported that 
a postoperative r t  dose of 30.6 Gy to anastomotic 
site and 50.4 Gy to the tumour bed concurrent with 
chemotherapy is sufficient and significantly reduces 
recurrence at both the anastomotic site and the tu-
mour bed. Besides esophageal cancer, the manage-
ment of anal canal cancer 24 has been successful 
using a r t  dose of 30–36 Gy concurrent with chemo-
therapy for microscopic disease eradication. That 
report concurs with Byfield 25 that chemotherapy can 
enhance the local effects of radiation to reduce the 
likelihood of spread from the primary, but also to 
reduce or limit micrometastasis. The r t  dose level 
sufficient to reduce relapse when delivered to the 
tumour bed concurrently with chemotherapy, while 
still balancing acceptable toxicity, is not yet clear. 
Total r t  doses of 45–50 Gy to the tumour bed have 
been reported 7,8,26 to be acceptable and are associ-
ated with tolerable treatment side effects.
We acknowledge several limitations of the pres-
ent study, including a small sample size and short 
follow-up. We also acknowledge the relative rarity 
of the patient group receiving postoperative chemo-
radiation for high risk of recurrence when preopera-
tive chemoradiation is recommended as the treatment 
of choice in many cancer treatment centers 27. How-
ever, the findings on treatment toxicity with the use 
of extended-volume r t  encompassing the anasto-
motic site postoperatively in high-risk cancer patients 
in the present prospective study confirm our centre’s 
previously reported retrospective experience that no 
addition treatment complications—including treat-
ment interruptions and gastrointestinal toxicity—
occur with the use of extended-volume r t  10.
t a b l e  iv  Pattern of relapse and sites of distal relapse in the study 
patients
Pattern of first relapse (N = 15)
Site [n (%)]
Anastomotic site only 0 (0)
Regional only 0 (0)
Distant only 6 (40)
Distal sites of first relapse (N = 6)
Organ [n (%)]
Liver 3 (50)
Lung 3 (50)
Brain 2 (33)
Pleura 1 (17)
Kidney (adrenals) 1 (17)
Abdomen 1 (17)
Bone 1 (17)
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fi g u r e  2   Disease-free survival in the study population to date.POSTOPERATIVE XRT IN HIGH-RISK ESOPHAGEAL CANCER
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The management of esophageal carcinoma, 
particularly with esophageal r t, has advanced since 
the end of the 1990s. A single treatment modality 
for patients with locoregional disease has now been 
demonstrated to be suboptimal 28,29. Tri-modality 
treatment offers the potential to improve outcomes 
for patients with high-risk disease. In employing 
tri-modality therapy, the controversy with respective 
to whether surgery should be performed before or 
after chemoradiotherapy remains a topic of debate. 
The current study demonstrating the safety and 
feasibility of extended-volume r t  and the associated 
encouraging early results in locoregional control 
suggest that this r t  regimen may be incorporated 
into future studies comparing neoadjuvant chemo-
radiotherapy with adjuvant chemoradiotherapy tri-
modality management.
5.  CONCLUSIONS
Extended-volume external-beam r t  encompassing 
the tumour bed and anastomotic site is feasible and 
safe for high-risk T3–4, N0–1 esophageal cancer 
patients post esophagectomy.
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